ClinicalTrials.gg
CompletedNCT04728334Updated Mar 3, 2025

A Phase 1 Dose Escalation and Expansion Study of AK117

A Phase 1 interventional study of AK117 in Neoplasms Malignant, sponsored by Akeso. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-03-03.

Sponsored by Akeso · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
49
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a multicenter, open label, single arm, Phase 1,dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacodynamics, PK, immunogenicity, and preliminary antitumor activity of AK117 administered intravenously to adult subjects with relapsed/refractory advanced or metastatic solid tumors or lymphomas.

Read the detailed description

The study comprises a dose escalation phase and a dose expansion phase. The phases will be conducted sequentially. Approximately 162 subjects will be enrolled in this study.

02

Conditions studied

  • Neoplasms Malignant

Browse trials for

Keywords

  • Antineoplastic Agents
  • Immunological
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.

This study's enrollment of 49 is below the median of 60 across 7,706 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Akeso is the lead sponsor of 157 studies on the registry; 67 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All Subjects

    1. Able to provide written and signed and any locally required authorization obtained from the subject/legal representative, which must be obtained prior to performing any protocol related procedures.
    2. Men or women aged ≥18 years and ≤75 at the time of study entry.
    3. (ECOG) performance status (PS) score of 0 or 1.
    4. ≥12 weeks.
    5. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures as specified in the protocol.
    6. Subjects must provide the tumor tissue samples after the diagnosis of solid tumor or lymphoma.
    7. Adequate organ function.
    8. Subjects with Solid Tumors:Subjects must have a or cytologically confirmed advanced solid tumor that is or relapsed to the current standard therapies, or for which no effective standard therapy is available. Subject must have at least 1 according to v1.1.
    9. Subjects with Lymphomas:Subjects must have histologically confirmed non-Hodgkin lymphoma(NHL), which may include transformed lymphoma, relapsed or refractory to hematopoietic stem cell transplantation, or at least 2 . Subjects must have disease that is measurable or assessable for response as per Lugano Classification 2014.

Exclusion criteria

Exclusion Criteria:

  • All Subjects

    1. Concurrent enrollment in another clinical study, unless it is an observational clinical study or the follow up period of an interventional study.
    2. Prior active within the previous 3 years except for the tumor for which a subject is enrolled in the study, and locally curable cancers that have been apparently cured.
    3. Receipt: The last cycle of anticancer therapy within 3 weeks prior to the first dose of product; Anticancer small molecule targeted agent, palliative local treatment for non-target lesions, non-specific immunomodulatory therapy within 2 weeks prior to the first dose of investigational product; Chinese medicines with anti-tumor indications within 1 week prior to the first dose of investigational product; Any major surgery within 4 weeks; RBC infusion within 3 months.
    4. or infiltration of brainstem and meninges;Metastasis or compression of the spinal cord; Active brain/central nervous system (CNS) metastases.
    5. Subjects with clinical symptoms or repeated drainage of pleural effusion, pericardial effusion or ascites.
    6. Cancer invasion of important surrounding organs or risk of esophageal tracheal fistula or esophageal pleural fistula.
    7. Known history of testing positive for (HIV) or known active acquired immunodeficiency syndrome.
    8. Known active or C infections (known positive HBsAg result or positive antibody with detectable HCV ribonucleic acid [RNA] results).
    9. Active or prior documented disease that may relapse.
    10. History of interstitial lung disease or noninfectious pneumonitis, except for those induced by radiation therapies.
    11. History of hemolytic anemia of any cause within 3 months prior to the first dose of investigational product.
    12. History of defects in RBC production, or production or metabolism.History of hemophagocytic lymphohistiocytosis.
    13. Previous or current gastrointestinal perforation, surgical incision, wound healing complications and bleeding events.
    14. Patients with cardio-cerebrovascular disease.
    15. Unresolved toxicities from prior anticancer therapy, defined as having not resolved to v5.0 Grade 0 or 1, or to levels dictated in the eligibility criteria with the exception of toxicities not considered a safety risk.
    16. Subjects with a condition requiring systemic treatment with either or other medications within 14 days prior to the first dose of investigational product.
    17. Subjects with prior use of , anti-PD-L1, anti-CTLA-4, or any other immuno-oncology agents, receipt of the following treatments or procedures: Use of immunotherapy or IO drug within 21 days prior to the first dose; Subjects had an irAE that resulted in permanent discontinuation of previous immunotherapy; Subjects had a history of grade 3 or higher irAE or cardiac, neurological, or ocular irAE of any grade at the time of prior immunotherapy; Prior to screening in this study, all AEs at the time of previous immunotherapy had not been completely remission or remission to grade 1; Subjects need to use other immunosuppressants other than glucocorticoids systematically to treat irAE.
    18. History of severe reactions to other mAbs.
    19. History of organ transplantation.
    20. Known allergy or reaction to any component of the investigational product formulation.
    21. Receipt any anticancer therapy targeting the 7/SIRPα signaling axis.
    22. Known history of mental illness, alcohol or drug abuse.
    23. Existing uncontrolled comorbiditions; Or a mental illness/social condition that may limit the subject's compliance with study requirements or affect the subject's ability to provide written .
    24. Other exclusion criteria for subjects with lymphoma:History of HTLV-1 infection.Subjects with primary or secondary central nervous system lymphoma. Subjects with history of hematopoietic stem cell transplantation.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    AK117 monotherapy

    AK117 monotherapy intravenous (IV) infusion - Weekly doses

    Drug: AK117

Interventions

  • DrugAK117

    An intravenous (IV) infusion of AK117 as monotherapy. All subjects will receive 4 weekly infusions (Days 1, 8, 15, and 22) of AK117 in each 28-day treatment cycle until unacceptable toxicity, documentation of confirmed progressive disease (PD), or subject withdrawal

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs)

    An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment.

    Time frame: From the time of informed consent signed through 30 days after the last dose of AK117

  2. Number of participants with a Dose Limiting Toxicity (DLT)

    DLTs will be assessed during the first 21 days of treatment for dose-escalation phase and are defined as toxicities that meet pre-defined severity criteria, and assessed as having a suspected relationship to study drug, and unrelated to disease, disease progression, inter-current illness, or concomitant medications .

    Time frame: During the first 21 days

Secondary outcomes

  1. Objective response rate (ORR)

    ORR defined as the proportion of subjects who achieves a best overall response of CR or PR, assessed by Investigator per RECIST Version 1.1 for solid tumor or the Lugano 2014 Classification for lymphoma

    Time frame: Up to 2 years

  2. Disease control rate (DCR)

    The DCR is defined as the proportion of subjects with CR, PR, or SD .

    Time frame: Up to 2 years

  3. Maximum observed concentration (Cmax) of AK117

    The endpoints for assessment of PK of AK104 include serum concentrations of AK117 at different timepoints after AK117 administration.

    Time frame: From first dose of AK117 through to 30 days after last dose of AK117

  4. Minimum observed concentration (Cmin) of AK117 at steady state

    The endpoints for assessment of PK of AK104 include serum concentrations of AK117 at different timepoints after AK117 administration.

    Time frame: From first dose of AK117 through to 30 days after last dose of AK117

  5. Number of subjects who develop detectable anti-drug antibodies (ADAs)

    The immunogenicity of AK117 will be assessed by summarizing the number of subjects who develop detectable antidrug antibodies (ADAs).

    Time frame: From first dose of AK117 through to 30 days after last dose of AK117

07

Study locations

1 site
  • FuDan University Shanghai Cancer Center
    Shanghai, Shanghai 200032, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Jan 2022, 10 months.

Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 61. This study's 10 months is below that.

Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2021
First posted
Jan 28, 2021
StartActual
Mar 23, 2021
Primary completionActual
Jan 25, 2022
CompletionActual
May 12, 2023
Last update
Mar 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04728334
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Jan 28, 2021
Start date
Mar 23, 2021
Primary completion
Jan 25, 2022
Completion
May 12, 2023
Last update
Mar 3, 2025

Study contacts

Jiong Wu, MD
principal investigator · Fudan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ligufalimab

Start the discussion